Previous Close | 1.1600 |
Open | 1.1800 |
Bid | 1.0100 x 2200 |
Ask | 1.2500 x 4000 |
Day's Range | 1.1600 - 1.2500 |
52 Week Range | 0.8400 - 1.6100 |
Volume | |
Avg. Volume | 969,356 |
Market Cap | 222.782M |
Beta (5Y Monthly) | 1.39 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1200 |
Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.20 |
CARLSBAD, Calif., May 09, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.
CARLSBAD, Calif., May 06, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month visual acuity results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), were presented at the 2024 Retinal Cel
CARLSBAD, Calif., May 02, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific T